Sarepta Therapeutics (SRPT) Insider Trading & Ownership → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free SRPT Stock Alerts $128.59 -1.64 (-1.26%) (As of 01:56 PM ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Sarepta Therapeutics (NASDAQ:SRPT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.40%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$10.74 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$4.34 M Get SRPT Insider Trade Alerts Want to know when executives and insiders are buying or selling Sarepta Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SRPT Insider Buying and Selling by Quarter Ad Porter & CompanyAI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.Simply click here now to read The Big AI Die-Up. Sarepta Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/11/2024Kathryn Jean BoorDirectorSell761$122.93$93,549.73 3/8/2024Hans Lennart Rudolf WigzellDirectorSell15,000$123.25$1,848,750.00 3/5/2024Stephen MayoDirectorSell3,135$122.96$385,479.60 3/1/2024Bilal ArifInsiderSell2,000$128.84$257,680.00 3/1/2024Ian Michael EstepanCFOSell1,200$128.30$153,960.00 11/3/2023Douglas S IngramCEOBuy25,225$79.36$2,001,856.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 11/3/2023Richard BarryDirectorBuy50,000$78.81$3,940,500.00 8/14/2023Michael Andrew ChambersDirectorBuy9,979$109.47$1,092,401.13 8/10/2023Michael Andrew ChambersDirectorBuy34,867$106.15$3,701,132.05 8/4/2023Hans Lennart Rudolf WigzellDirectorSell15,000$106.72$1,600,800.00 (Data available from 1/1/2013 forward) SRPT Insider Trading Activity - Frequently Asked Questions Who is on Sarepta Therapeutics's Insider Roster? The list of insiders at Sarepta Therapeutics includes Bilal Arif, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry, and Stephen Mayo. Learn more on insiders at SRPT. What percentage of Sarepta Therapeutics stock is owned by insiders? 7.40% of Sarepta Therapeutics stock is owned by insiders. Learn more on SRPT's insider holdings. Which Sarepta Therapeutics insiders have been buying company stock? The following insiders have purchased SRPT shares in the last 24 months: Douglas S Ingram ($2,001,856.00), Michael Andrew Chambers ($15,755,773.78), and Richard Barry ($3,940,500.00). How much insider buying is happening at Sarepta Therapeutics? Insiders have purchased a total of 223,341 SRPT shares in the last 24 months for a total of $21,698,129.78 bought. Which Sarepta Therapeutics insiders have been selling company stock? The following insiders have sold SRPT shares in the last 24 months: Bilal Arif ($257,680.00), Hans Lennart Rudolf Wigzell ($3,449,550.00), Ian Michael Estepan ($153,960.00), Kathryn Jean Boor ($93,549.73), and Stephen Mayo ($479,790.96). How much insider selling is happening at Sarepta Therapeutics? Insiders have sold a total of 37,954 Sarepta Therapeutics shares in the last 24 months for a total of $4,434,530.69 sold. Which members of congress are trading Sarepta Therapeutics? Josh Gottheimer (D-NJ) has bought shares of Sarepta Therapeutics in the last year totaling $8,000. Josh Gottheimer (D-NJ) and Daniel S. Goldman (D-NY) have sold shares totaling $40,500. More Insider Trading Tools from MarketBeat Related Companies: United Therapeutics Insider Buying Karuna Therapeutics Insider Buying Catalent Insider Buying Viatris Insider Buying Teva Pharmaceutical Industries Insider Buying Roivant Sciences Insider Buying Jazz Pharmaceuticals Insider Buying Elanco Animal Health Insider Buying Cerevel Therapeutics Insider Buying BeiGene Insider Buying Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Stocks Insiders Are Buying That Analysts LoveInsider Selling of Amazon Spikes in Q1, but it's Not Time to Sell3 Small Dividend Paying Banks Insiders are Buying3 Stocks Insiders are Buying at New HighsInsider selling at JPM: A Closer Look Amidst Historic CEO Sale This page (NASDAQ:SRPT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.